Business Daily Media

Men's Weekly

.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

Deleted

This Press release has been killed

Ausom Launches L1 ABE Electric Scooter with Full German Road Approval

HONG KONG SAR - Media OutReach Newswire - 15 October 2025 - Ausom’s new L1 ABE electric scooter is now available with full road approval in Germany—and for a limited time, it’s launching with spec...

Top Hong Kong Hotels 2025 | Regent Hong Kong Achieves Prestigious Recognition in Condé Nast Traveler Awards

HONG KONG / SINGAPORE - Media OutReach Newswire - 15 October 2025 - Regent Hong Kong proudly announces its recognition in the Condé Nast Traveler Readers' Choice Awards 2025 as one of the top 5 be...

Prudential NextGen Aces featured Exclusive On-Court Session and Panel Series with tennis icons Andre Agassi and Aryna Sabalenka

HONG KONG SAR - Media OutReach Newswire - 15 October 2025 - Prudential plc ('Prudential'), a leading life and health insurer and asset manager, today hosted the Prudential NextGen Aces, an event t...

OPPO ColorOS 16 Set for Global Unveil: A New Era of Smoothness, Intelligence, and Seamless Connectivity

SHENZHEN, CHINA - Media OutReach Newswire - 15 October 2025 - OPPO has revealed its first look at ColorOS 16, the latest version of its mobile operating system, launching with the upcoming Find X9...

Xsolla Brings Exclusive Event To Thailand With Xsolla Connect Bangkok: A Global Games Industry Gathering

Exclusive Event Brings Developers, Publishers, Investors, And Industry Leaders Together to Help Shape The Future Of Gaming BANGKOK, THAILAND - Media OutReach Newswire - 15 October 2025 - Xsolla, a...

APAC Employee Medical Plan Costs to Stabilise in 2026 After Two Years of Sharp Increase, Aon reports

China, India, Singapore, the Philippines and Vietnam projecting lower increases than previous year Cardiovascular diseases, gastrointestinal conditions and cancer are top medical ...

Singapore and Shanghai Professional Bodies Sign MOU to Empower Enterprises Through Cross-Border Collaboration

SINGAPORE - Media OutReach Newswire - 15 October 2025 – Professional and business communities from Singapore and Shanghai came together today in a landmark collaboration to deepen ties and empower...

Watch Exchange Turns Luxury Timepieces Into Hope: Charity Drive to Raise At Least S$100K for Elderly Care

"Give Time, Share Hope" campaign transforms dormant watches into tangible support for Geylang East Home for the Aged SINGAPORE - Media OutReach Newswire - 15 October 2025 – As Singapore's populati...

Coca-Cola: First in Hong Kong in Recycling Plastic Bottles to Create New Ones Leveraging Its Own Facilities

Continuing to advocate for and invest in well-designed collection systems to help reduce beverage packaging waste HONG KONG SAR - Media OutReach Newswire - 15 October 2025 - Coca-Cola in Hong Kong...

Qantas to Serve Nan’s Davidson Plum Cookie

Lake Macquarie, NSW (Awabakal Country): From a single mother’s kitchen bench to supermarket shelves, Wiradjuri entrepreneur Terri-Ann “Tezzi” Dani...

Minns Labor Government shutting down the Business Connect program

The NSW Opposition is concerned that the Labor government will shut down a support program that has assisted New South Wales businesses. In a media ...

Samsara Eco appoints Dr. Lars Kissau as General Manager for Asia

Australian biotech innovator Samsara Eco has announced the appointment of Dr Lars Kissau as its first General Manager of Asia. Based in Singapore...

From the first bounce to the final siren - small business lessons from the AFL Grand Final

The AFL Grand Final is one of the most anticipated days on the sporting calendar. This Saturday, the Geelong Cats and Brisbane Lions will battle i...

Australia’s top finance leaders recognised as CFO role expands

Amid surging regulatory demands and rapidly evolving industry, Australia’s most influential Chief Financial Officers will be honoured at the inaug...

Why outdated security leaves small businesses exposed to crime

Small and medium businesses in Australia are under increasing pressure to address security gaps that criminals readily exploit. An unlocked door, an...